Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs
Launched by NOVO NORDISK A/S · Dec 5, 2011
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 diabetes mellitus for at least 12 months
- • HbA1c between 7.5-14.5% (inclusive) at screening
- • Insulin naïve
- • An antidiabetic regimen that has been stable for at least 3 months prior to screening
- • An antidiabetic regimen that includes a minimum of 2 OADs
- Exclusion Criteria:
- • Use of any insulin preparations within the past 6 months
- • Active proliferative retinopathy or maculopathy requiring treatment within 6 months prior to screening
Trial Officials
Global Clinical Registry (GCR, 1452)
Study Director
Novo Nordisk A/S
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pachuca, , Mexico
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
